Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai's Perampanel Phase III Outcomes Show Efficacy, But May Not Meet Company Hype

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Eisai Co. Ltd. released generally positive results of a Phase III trial for epilepsy drug perampanel, a compound which the company has promoted heavily to investors and analysts, but discouraging results on dose-dependent efficacy may contribute to an underperformance of the hyped drug, according to a Tokyo pharma analyst

You may also be interested in...



With New Mechanism, Can Eisai’s Fycompa Make Its Mark In Epilepsy?

Efficacy results were not uniformly positive in pivotal trials of newly approved perampanel, but FDA explains that may be due to high placebo rates in some international sites.

Eisai Wins FDA Approval For Novel, Once-Daily Seizure Drug Fycompa

Eisai’s Fycompa becomes only the second drug with a new mechanism of action approved by FDA for epilepsy in the last decade.

Post-Aricept Patent Expiry, Eisai Starts Comeback With Roll-Out Of New Anti-Epileptic Fycompa In Europe

Eisai hopes the launch of its first-in-class anti-epileptic drug Fycompa in Britain and other European markets will help offset revenues lost after its Aricept Alzheimer’s therapy went off patent in the region earlier this year, and signal a new phase of growth for the Japanese company.

Related Content

UsernamePublicRestriction

Register

CO180755

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel